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Background: QFT-Plus is a recently developed next-generation QuantiFERON-TB Gold In-Tube 
(QFT-GIT) test. Unlike the QFT-GIT test, it includes a TB2 antigen tube with peptides that may 
stimulate CD8+ T cells. This study evaluated the diagnostic performance of QFT-Plus and compared it 
with that of QFT-GIT.
Methods: QFT-Plus and QFT-GIT tests were performed in 33 patients with active tuberculosis (TB) and 
57 healthy controls including subjects with latent TB infection (LTBI). Positivity and negativity of IFN-γ 
responses were compared between tests, and total concordance of the outcome was analyzed.
Results: Positive and negative outcomes of QFT-Plus and QFT-GIT tests showed substantial agreement 
(91.1%, kappa=0.8). The sensitivity and the specificity of QFT-Plus (93.9% sensitivity, 92.6% specificity) 
were similar with those of QFT-GIT (93.9% sensitivity, 100% specificity). Of eight discordant results, five 
(5.56%) and three (3.3%) were positive in QFT-GIT alone and QFT-plus alone, respectively. Reactivity in 
the TB2 tube contributes to the difference between QFT-GIT and QFT-Plus. Median IFN-γ production 
in TB2 (10.0 IU/mL in TB, 3.850 IU/mL in LTBI, P=0.001) is significantly higher in the TB group than 
the LTBI group. The QFT-Plus did not clearly discriminate between active TB and latent TB, although it 
showed significantly lower IFN-γ concentrations compared with the QFT-GIT in individuals with LTBI 
(3.850 vs. 7.205 IU/mL).
Conclusions: Similar accuracy of detecting Mycobacterium tuberculosis infection was observed for QFT-
Plus and QFT-GIT tests in immunocompetent patients and healthy controls, including those with LTBI. 
Improved efficacy for identifying M. tuberculosis infection was not found with the QFT-Plus, but further 
studies in a larger population may confirm the clinical significance of positive response in the TB2 tube of 
QFT-Plus.
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Introduction
Tuberculosis (TB) is a global disease caused by infection 
with Mycobacterium tuberculosis (M. tb) (1). There were an 
estimated 10 million cases of TB and 1.3 million deaths 
worldwide in 2017. While latent TB infection (LTBI) has 
no risk of transmission, it is a reservoir of TB disease that 
may progress to active TB in 5–15% of infected subjects 
during their lifetime (2). Thus, early diagnosis and 
treatment of LTBI is important for ultimately controlling 
TB (3). In South Korea, TB incidence and death rate are 
still the highest among Organization for Economic Co-
operation and Development (OECD) countries (incidence: 
70/100,000, death: 5/100,000), although they decline every 
year (1,4). Based on the seventh Korean National Health 
and Nutrition Examination Survey, estimated LTBI 
prevalence in South Korea is 33.2% (5). The prevalence 
of LTBI using the interferon-γ release assay (IGRA) 
test ranged from 2.1% to 34% (total 11.6%) among 
congregated settings (6). The Korean Centers for Disease 
Control and prevention established a TB prevention 
project by providing employees working at medical 
institutions or daycare centers with LTBI checkups and 
treatment (7).
Diagnosis of LTBI has been performed by tuberculin 
skin test (TST) and T-cell IGRA. Compared with the 
TST, IGRAs only require one patient visit and do not 
yield false-positive results in Bacillus-Calmette-Guerin 
vaccinated subjects (8). However, IGRA has poor sensitivity 
in immunocompromised patients and children (9,10). It 
cannot distinguish between active TB and LTBI (8) and 
poorly correlates with developing active disease (11). To 
improve the efficacy of IGRA, QuantiFERON-TB Gold 
Plus (QFT-Plus) has been recently developed as a next-
generation QuantiFERON-TB Gold In-Tube (QFT-GIT) 
test. QFT-Plus contains two TB-specific antigen coated 
tubes, TB1 and TB2.The antigen tubes contain 6-kDa 
early secretory antigenic target (ESAT-6) and 10-kDa 
culture filtrate protein (CFP-10), but not TB7.7. The long 
synthetic peptides in TB1 tubes are designed to stimulate 
CD4-T cells, as does QFT-GIT. However, the QFT-Plus 
includes an additional TB2 antigen tube which contains 
six short peptides that may also induce CD8 T-cell specific 
immune responses (12). Test performance of the QFT-Plus 
has mostly been reported in low incidence settings (13-16) 
or in immuncompromised patients (17). The diagnostic 
sensitivity of QFT-Plus was similar with QFT-GIT in a 
country where TB prevalence is low (13,14), but the data on 
the performance of two assays are controversial; Tsuyuzaki 
et al. reported that QFT-Plus revealed higher positivity 
and increased IFN-γ production compared with QFT-GIT 
in TB contact investigation (18). However, lower IFN-γ 
concentration was observed by QFT-Plus compared with 
QFT-GIT based on the report by Yi et al. (15). In addition, 
evaluation of QFT-Plus is still lacking in countries with 
intermediate/high TB burden. Therefore, the new version 
of IGRA, QFT-Plus needs to be investigated in diverse 
population including endemic settings.
In this study, the performance of QFT-Plus was tested 
in immunocompetent subjects including patients with 
active TB, individuals with LTBI, and non-infected healthy 
controls. IFN-γ responses to TB1 and TB2 antigens were 
analyzed alone and combined. The efficacy of the QFT-
Plus for identifying M. tb infection was compared with the 
performance of QFT-GIT, a conventional IGRA.
Methods
Enrollment of study subjects
This study was approved by the ethical committee of 
Chuncheon Sacred Heart Hospital (Approval number: 
2017-27). All subjects gave written informed consent to 
participate in this study. Enrolled patients with active 
TB were classified as “confirmed TB” and “clinical TB”. 
“Confirmed TB” was diagnosed by a positive culture for 
M. tb from sputum or pleural effusion. “Clinical TB” was 
identified based on clinical and radiologic criteria, which 
included typical cavities and branching centrilobular 
nodules evident on high-resolution computed tomography, 
and appropriate responses to anti-TB treatment (19). 
Extent of lung lesion was divided into three; mild (one-third 
of lung field), moderate (one-half of lung field) and severe 
(more than half of lung field). Individuals with diabetes 
mellitus, malignancy, end-stage renal disease, or those who 
received immunosuppressive therapy such as anti-cancer 
chemotherapy or steroids were excluded.
LTBI was characterized by a positive QFT-GIT (Qiagen, 
Hilden, Germany) in the absence of radiologic findings or 
clinical symptoms of active TB. Healthy controls consisted 
of healthy adults with a negative QFT-GIT who did not 
have any contact with active pulmonary TB patients and 
had no respiratory symptoms. Finally, we prospectively 
enrolled 33 patients with active TB, 30 LTBI subjects, 
and 27 healthy controls. Table 1 shows the demographic 
information of the study population.
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QuantiFERON-TB Gold In Tube (QFT-GIT) and 
QuantiFERON-TB Gold Plus (QFT-Plus)
The QFT-GIT and QFT-Plus tests were performed 
in accordance with the manufacturer’s instructions. 
Briefly, whole blood (8 mL in total) was drawn into two 
blood-collecting vessels containing lithium-heparin. 
1 mL of blood samples were collected in each tube and 
incubated at 37 ℃ for 16–24 hours. Conventional QFT-
GIT consisted of three tubes: nil (no antigen, negative 
control), TB, and mitogen (positive control). QFT-Plus 
consisted of four tubes: nil, TB1, TB2, and mitogen. 
After incubation, the tubes were centrifuged at 2,000 ×g 
for 10 minutes. A total of 300 μL of plasma supernatant 
was harvested and stored at −80 ℃ until enzyme-linked 
immunosorbent assay (ELISA) was performed. The frozen 
plasma samples were thawed at room temperature and re-
centrifuged at 1,750 ×g for 10 minutes. Every sample was 
analyzed in duplicate and samples from 8 subjects were on 
a single plate in each run of ELISA. The optimal density 
of each well was measured on a plate reader (Multiskan JX, 
Thermo Scientific) and the concentration of IFN-γ was 
determined using a QFT-GIT analysis software provided 
by the manufacturer. The concentration of released IFN-γ 
in each tube was calculated by subtracting the value of the 
nil tube. The results were interpreted as positive when the 
IFN-γ concentration was ≥0.35 IU/mL and ≥25% of the 
nil value.
Statistical analysis
For the purpose of the study, we computed a sample size of 
81 patients, given an α error of 5% (one-sided) and a β error 
of 80%, with a standard deviation for the sensitivity equal to 
93% and a non-inferiority limit of 10%. After considering 
potential drop-outs (5%), required minimum sample size of 
85 was estimated. Data were analyzed using SPSS software 
(V 21.0; SPSS, Chicago, IL, USA) and GraphPad Prism 6 
(GraphPad, San Diego, CA, USA). Data are presented as 
median and interquartile range (IQR). Categorical variables 
were analyzed using the Chi-Square test and Kruskal-Wallis 
test with Dunn’s multiple comparison. Agreement between 
the QFT-GIT and QFT-Plus tests (test concordance) was 
assessed by kappa statistics (κ coefficients); κ≤0.20 was 
considered “slight”; 0.20<κ≤0.40 was considered “fair”, 
0.40<κ≤0.60 was considered “moderate”, 0.60<κ≤0.80 was 
considered “substantial”, and 0.80<κ≤1.00 was considered 
“optimal”.
Results
Characteristics of study participants
Among 33 patients with active TB, M. tb was identified by 
acid fast bacilli (AFB) staining and culture (one patient had an 
extrapulmonary form) in 15 patients (Table 1). The other 18 
patients were clinically diagnosed with TB. All patients were 
BCG-vaccinated. The extent of lung lesions was divided into 
thirds (mild, moderate, and severe), and 29 patients (87.9%) 
had mild pulmonary lesions constituting less than one-
thirds of the lung field. Age and gender distributions were 
not matched among the three groups; patients with active 
TB were younger than LTBI subjects and healthy controls 
(median age: 17 in active TB, 41 in LTBI, 42 in healthy 
control). The active TB group included more men compared 
with the LTBI and healthy control groups (active TB: 87.9%, 
LTBI: 13.3%, healthy control: 18.5%).
Results of QFT-GIT and QFT-Plus tests in study subjects
Among a total of 90 subjects, 61 (61/90, 67.8%) and 59 
(59/90, 65.6%) subjects showed positive IFN-γ responses 
(cut-off value 0.35 IU/mL) with the conventional QFT-
GIT and QFT-Plus, respectively. Both tests had positive 
outcomes in 31 patients with active TB, but different 
outcomes were observed in LTBI and control groups. QFT-
GIT gave 30 positive results with LTBI, whereas QFT-Plus 
gave 26 and 2 positive results in LTBI and control groups, 
Table 1 Basic characteristics of study populations
Characteristics 
Active TB 
(n=33)
LTBI  
(n=30)
HC  
(n=27)
Sex, M/F 29/4 4/26 5/22
Age (IQR) 17 [17–24] 41 [36–46] 42 [35–46]
Extrapulmonary TB, n (%) 2 (6.1)
AFB smear (+), n (%) 3 (9.1)
AFB culture (+), n (%) 15 (45.5)
Cavity, n (%) 3 (9.1)
Lung lesion, n (%)
Mild 29 (87.9)
Moderate/severe 4 (12.1)
The numbers in brackets represent percentages in each 
category. AFB, acid fast bacilli; LTBI, latent tuberculosis 
infection; HC, healthy control; M/F, male/female; IQR, 
interquartile range; n, number. 
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Table 2 QFT-Plus response among different groups
Variable
Active TB (n=33)
LTBI (n=30) HC (n=27)
Total AFB Cx(+) (n=16) AFB Cx(−) (n=17)
QFT-GIT
TB+ 31 (93.9) 15 (93.8) 16 (94.1) 30 (100.0) 0 (0.0)
QFT-Plus
TB1+ or TB2+ 31 (93.9) 15 (93.8) 16 (94.1) 26 (86.7) 2 (7.4)
TB1+ 29 (87.9) 13 (81.3) 16 (94.1) 26 (86.7) 0 (0.0)
TB2+ 31 (93.9) 15 (93.8) 16 (94.1) 24 (80.0) 2 (7.4)
Only TB1+ 0 (0.0) 0 (0.0) 0 (0.0) 2 (6.7) 0 (0.0)
Only TB2+ 2 (6.1) 2 (12.5) 0 (0.0) 0 (0.0) 2 (7.4)
TB1 and TB2 29 (87.9) 13 (81.3) 16 (94.1) 24 (80.0) 0 (0.0)
The numbers in brackets represent percentages in each category. AFB, acid fast bacilli; Cx, culture; n, number; LTBI, latent tuberculosis 
infection; HC, healthy control; QFT-GIT, QuantiFERON-TB Gold In-Tube; QFT Plus, QuantiFERON-TB Gold Plus. 
Table 3 Concordance between QFT-GIT and QFT-Plus
QFT-GIT
QTF Plus TB1 TB2
P N κ P N κ P N κ
P 56/90 5/90 0.8 55/90 6/90 0.855 54/90 7/90 0.755
N 3/90 26/90 0/90 29/90 3/90 26/90
P, positive, N, negative; QFT-GIT, QuantiFERON-TB Gold In-Tube; QFT Plus, QuantiFERON-TB Gold Plus.
respectively (Table 2).
The sensitivity of QFT-Plus in active TB cases, based 
on the response to either TB1 or TB2, was 93.9%. The 
specificity calculated on healthy controls was 92.6%. These 
values are similar to those of the QFT-GIT test (sensitivity 
93.9%, specificity 100%). Total concordance between 
the two tests was substantial (κ=0.8) (Table 3). Each of the 
QFT-Plus TB antigens showed similar concordance with 
QFT-GIT TB antigen in all subjects (TB1: κ=0.855, TB2: 
κ=0.755) (Table 3). In active TB, substantial or moderate 
agreement was achieved based on TB antigen (TB1: 
κ=0.637, TB: κ=0.468).
Based on the responses to TB1 and TB2 antigens, IFN-γ 
responses were analyzed for the different groups; positive 
responses to both TB1 and TB2 antigens were found in 
29 patients with active TB (87.9%) and 24 subjects with 
LTBI (81.3%) (Table 2). The proportion of responders to 
TB1 antigen were similar for active TB and LTBI (87.9% 
vs. 86.7%), whereas the proportion of responders to TB2 
antigen was higher with active TB compared with LTBI 
(93.9% vs. 80.0%). Interestingly, two exclusive responders 
to TB2 alone were identified with active TB (2/33, 6.1%). 
A higher proportion of patients responded to TB2 antigen 
compared withTB1 (TB1 vs. TB2; 87.9% vs. 93.9%) in 
active TB, whereas fewer TB2 responders were observed in 
LTBI (TB1 vs. TB2; 86.7% vs. 80.0%) (Table 2).
Individual discrepancies of results between QFT-GIT and 
QFT-Plus
The alternative IGRA tests yielded discrepant results in 
eight study subjects. Five (5/8) subjects, including one 
patient with active TB and four individuals with LTBI, were 
IFN-γ positive by QFT-GIT test, whereas they did not 
respond to antigens of the QFT-Plus. Five subjects with 
positive QFT-GIT and negative QFT-Plus showed weak 
positivity by QFT-GIT test; the detection levels of IFN-γ 
were around 1 IU/mL or below. Two healthy controls and 
one patient with active TB (3/8) showed positive IFN-γ 
responses by the QFT-Plus test while negative results 
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were observed in the QFT-GIT test (Table 4). All study 
participants who had QFT-Plus positive and QFT-GIT 
negative (G−P+) results responded to TB2 antigen alone in 
the QFT-Plus test (Table 4).
Comparison of quantitative IFN-γ responses between QFT-
GIT and QFT-Plus tests
The median value of IFN-γ discriminated between QFT-
GIT and QFT-Plus antigens in subjects with LTBI 
(Figure 1A); QFT-GIT antigen-induced IFN-γ responses 
(7.205 IU/mL, IQR: 3.858–10.00) were significantly 
higher than those induced by TB1 (3.485 IU/mL, IQR: 
1.728–6.945, P<0.05) and TB2 (3.850 IU/mL, IQR: 
0.705–7.023 IU/mL, P<0.05) in QFT-Plus. However, no 
significant differences were found in patients with active TB 
and healthy controls (Figure 1B,C).
Comparative analyses based on antigen tubes showed 
that all TB antigens of QFT-Plus and QFT-GIT induced 
significantly higher IFN-γ responses in active TB and 
individuals with LTBI compared with controls (Figure 2). 
In response to TB2 in QFT-Plus, median IFN-γ responses 
were significantly higher in patients with active TB than 
in subjects with LTBI (10.00 IU/mL, IQR: 4.97–10.00 vs. 
3.85 IU/mL, IQR: 0.70–7.023, P<0.05 Figure 2B). IFN-γ 
responses to TB1were not different between patients with 
active TB and subjects with LTBI (10.00 IU/mL, IQR: 
3.225–10.00 vs. 3.485 IU/mL, IQR: 1.728–6.945, P>0.05, 
Figure 2A). Likewise, median IFN-γ responses did not vary 
between active TB and LTBI by QFT-GIT tests (P>0.05, 
Figure 2C).
Discussion
We examined the efficacy of the recently upgraded IGRA, 
QFT-Plus, and compared it with QFT-GIT in a setting 
with intermediate TB burden. Although the CD8-T cell 
specific immune responses might be induced by additional 
TB2 peptides in QFT-Plus, the efficacy of QFT-Plus 
did not seem superior to that of conventional QFT-GIT. 
Substantial agreement with the same sensitivity and similar 
specificity was observed between the two assays.
Table 4 Cases with discrepancies between QFT-GIT and QFT-
Plus (indicated values: interferon-γ in IU/mL)
Variable QFT-GIT
QFT-Plus
TB1 TB2
G+P−
LTBI 0.42 0.17 0.15
0.57 −0.29 0.21
0.95 −0.79 −1.85
1.03 −0.14 −0.07
Active TB 0.43 0.14 0.17
G−P+
HC −0.34 −0.09 0.63
0.07 −0.32 0.87
Active TB −0.01 −0.03 2.02
LTBI, latent tuberculosis infection; HC, healthy control; QFT-
GIT, QuantiFERON-TB Gold In-Tube; QFT Plus, QuantiFERON-
TB Gold Plus; G+P−, QFT-GIT positive and QFT-Plus negative 
group; G−P+, QFT-GIT negative and QFT-Plus positive group.
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Figure 1 Quantitative IFN-γ response of patients with active TB (B), subjects with LTBI (A), and healthy controls (C). Horizontal lines in 
red indicate median production and dotted lines indicate cut-off (Log10 0.35=−0.456). *, P<0.05. IFN, interferon; IU, international unit; 
LTBI, latent tuberculosis infection; HC, healthy control; QFT-GIT, QuantiFERON-TB Gold In-Tube. 
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Figure 2 Quantitative IFN-γ responses to QFT-Plus antigen TB1 (A), TB2 (B), and QFT-GIT antigen (C). Horizontal lines in red indicate 
median production and dotted lines indicate cut-off (Log10 0.35=−0.456). *, P<0.05; ***, P<0.001. IFN, interferon; IU, international unit; 
LTBI, latent tuberculosis infection; HC, healthy control; QFT-GIT, QuantiFERON-TB Gold In-Tube; NS, not significant.
Several studies have reported variable diagnostic 
outcomes in a borderline range (0.20–0.99 IU/mL) by 
QFT-GIT tests, and retesting with a raised cut-off for 
positivity has been recommended to reduce false positives 
(20-24). Conversions and reversions were detected in all 
high, intermediate, and low-incidence settings (22-24). 
In our study, all discordant results between QFT-GIT 
and QFT-Plus were observed at 0.4–1.0 IU/mL, except 
for one patient with active TB whose IFN-γ response to 
TB2 was 2.0 IU/mL. This suggests that total concordance 
between the two tests may be increased by a raised cut-off 
(>1.0 IU/mL). Meanwhile, minus values of the IFN-γ (TB-
Nil) were observed in some patients, and it was due to 
higher IFN-γ levels of Nil tubes compared with TB antigen 
tubes. The result with over 8 IU/mL of Nil IFN-γ should 
be interpreted as indeterminate (25). In this study, all the 
Nil IFN-γ values were less than 8 IU/mL, and the minus 
values of IFN-γ (TB-Nil) were regarded as negative results.
The IFN-γ responses to TB2 alone were associated 
with active TB, whereas positive results by QFT-Plus in 
the LTBI group were mainly due to responses to TB1.
A previous study performed in Italy, a low TB endemic 
country (13), showed similar data as ours; the majority of 
subjects with LTBI responded to TB1 antigen stimulation 
(98%) and no subjects with LTBI showed exclusive response 
to TB2 antigen. Only patients with active TB responded 
to TB2 antigen alone, suggesting that CD8 T cells may 
play a role in recognition of replicating M. tb. Several 
studies reported that CD8 T cell response correlates with 
mycobacterial load and declines after TB therapy (11,26,27). 
Day et al. found that M. tb-specific CD8 T cells increased 
in patients with active TB, and specific polyfunctional IFN-
γ+IL-2+TNF-α+CD8 T cells were impaired in patients with 
smear positive TB (11,26). In addition, successful treatment 
led to increased polyfunctional CD8 T cells and reduction 
of single IFN-γ producing cells (26,27). Theoretically, 
mycobacteria specific-CD8 T cells can secrete IFN-γ aside 
from CD4 T cells. Barcellini et al. showed that IFN-γ can 
be amplified by CD8 T cell-stimulating antigens (28). In 
this study, there was no significant difference in IFN-γ 
responses between TB1 and TB2 antigen stimulation, in 
accordance with a study in Japan (15). Differences in the 
proportions of smear-positive patients may explain the 
discrepancy among studies.
The QFT-Plus does not contain TB 7.7, which is 
included in the QFT-GIT. The absence of TB7.7 in 
QFT-Plus antigen tubes might cause different IFN-γ 
responses in LTBI groups, although the active TB and 
control groups were not affected by the antigen difference. 
Patients with active TB had higher levels of IFN-γ by 
QFT-GIT than by QFT-Plus in Japan and Germany 
(14,15), whereas similar responses were found between the 
alternative assays in Italy (13).
When comparing quantitative levels of IFN-γ, patients 
with active TB showed statistically higher IFN-γ levels 
to TB2 stimulation compared to individuals with LTBI. 
A similar study was reported in the Netherlands (29); 
median IFN-γ production byTB2 was significantly higher 
with active TB than with LTBI without prophylactic 
therapy. However, active TB and LTBI were not clearly 
differentiated by the QFT-Plus test due to overlapping 
responses to the TB1 antigen. Increased IP-10 responses 
were found in patients with active TB and high bacterial 
loads or radiologic severity compared to patients with a 
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clinical diagnosis (30). However, IP-10 responses by QFT-
Plus did not distinguish between active TB and LTBI (30).
More data are needed to demonstrate the utility of QFT-
Plus distinct from QFT-GIT in a larger sample size, and 
the variability of QFT-Plus should be evaluated. In this 
study, the number of subjects was limited as the enrollment 
of subjects had been conducted in a single institution within 
a restricted period. More patients and controls who match 
general backgrounds including age distribution should be 
participated for validation of the study results.
In conclusion, we confirmed that QFT-Plus and QFT-
GIT assays have excellent agreement and similar accuracy 
for identifying M. tb infection in immunocompetent 
subjects in South Korea, which has intermediate TB 
prevalence. IFN-γ responses exclusive to TB1 or TB2 
antigens were observed in LTBI or active TB, respectively. 
Further surveys are needed to evaluate the role of QFT-
Plus in determining patients with different stages of M. tb 
infection or to monitor treatment effect.
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